Syndax Pharmaceuticals Inc (SNDX) · Nov 2, 2026 · Exec change
CFO appointment — Starts November 9, 2026; $543,000 base salary plus up to 45% bonus
Syndax’s CFO change brings in Aaron Ondrey, an experienced biotech finance executive, as the company scales two growing commercial products.
Syndax is transitioning from launch-stage biotech to a commercial oncology company, building revenue around Revuforj and Niktimvo while advancing new indications and pipeline assets. Its prior CFO, Keith Goldan, had led finance since June 2022, including the company’s move through its first product approvals and commercialization phase.
The filing confirms a real CFO transition, not a routine title change. Aaron Ondrey is set to become CFO on November 9, replacing a finance chief who had been in place through the company’s commercial ramp. 〔0〕
The incoming hire fits the company’s next operating phase, but the filing gives no reason for the change. Ondrey’s background includes biotech commercial finance, capital allocation and supporting product launches, which is relevant as Syndax scales two approved medicines; however, the agreement does not disclose whether Goldan resigned, was terminated, or is moving to another role.
The package is meaningful but not itself a strategic signal. Ondrey receives a $543,000 salary, eligibility for a bonus of up to 45% of salary, and an inducement option for 270,000 shares subject to board approval and standard vesting. 〔1〕 〔2〕 The agreement also provides nine months of severance for a qualifying termination and 18 months if termination follows a change in control, which is standard executive-retention protection but adds cost if the transition fails. 〔3〕 〔4〕
Bottom line: This is a consequential leadership handoff during Syndax’s commercial scale-up, but not a change to the product or financial story. The experienced replacement limits the concern, while the unexplained departure and timing make the event modestly negative until management explains the transition and demonstrates continuity.
Ondrey starts as CFO, November 9
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!